Advanced Peptide Modifications Drive Therapeutic Innovation Across Diverse Disease Areas

Peptides bridge the therapeutic gap between small molecules and biologics, offering high specificity, favorable safety, and diverse biological functions. Despite their promise, challenges like short half-life, poor bioavailability, and enzymatic degradation have historically limited their clinical utility. Current standard-of-care often involves small molecules with off-target effects or large biologics with immunogenicity concerns. This review explores how advanced modifications and delivery strategies are overcoming these limitations, unlocking the full therapeutic potential of peptides across critical areas like metabolic disorders, oncology, and infectious diseases.

This comprehensive review systematically synthesizes recent progress in peptide therapeutics, analyzing their inherent advantages and limitations. The authors employed a structured search strategy across online databases to identify pertinent papers, focusing on advancements in peptide modification and application. The review discusses various strategies for peptide design, including the incorporation of noncanonical amino acids and the development of advanced drug delivery systems. It also covers the roles of therapeutic peptides in specific disease contexts such as diabetes, cancer, and antiviral and antimicrobial therapies, alongside the emerging field of peptide-drug conjugates.

The review elucidates how strategic modifications significantly enhance peptide drug properties, addressing key limitations. It details the utility of noncanonical amino acids in improving proteolytic stability, receptor affinity, and pharmacokinetic profiles, thereby expanding the chemical space and therapeutic potential of peptides. Advances in chemical synthesis and structural modification techniques are highlighted as critical drivers for developing novel peptide scaffolds with enhanced efficacy and reduced off-target effects. Furthermore, the paper emphasizes the transformative impact of sophisticated drug delivery technologies, such as sustained-release formulations and targeted delivery systems, in overcoming bioavailability challenges and improving patient compliance.

The review underscores the pivotal role of peptide-drug conjugates in targeted therapy, particularly in oncology, by enabling precise delivery of cytotoxic agents to tumor cells while minimizing systemic toxicity. It also outlines the expanding applications of therapeutic peptides in managing diabetes through novel GLP-1R and GIPR agonists, combating antimicrobial resistance with new AMPs, and developing potent antiviral agents. The synthesis of these advancements collectively positions peptides as a rapidly evolving and highly promising class of therapeutics.